Literature DB >> 15581748

Adverse drug reactions due to prolonged antibiotic therapy for malignant external otitis.

Renata Shichmanter1, Edward B Miller, Zvi Landau.   

Abstract

BACKGROUND: Malignant external otitis (MEO) is a life-threatening infection requiring prolonged antibiotic therapy. Adverse drug reactions (ADR) occur frequently in patients treated with long-term antibiotics, often limiting treatment effectiveness. We attempted to identify and categorize the frequency and type of ADR in patients undergoing treatment for MEO in an attempt to improve overall treatment of individuals with this disorder.
METHODS: Twenty-one patients with MEO who were treated during a 10-year period at our institution were identified retrospectively. Records were reviewed to determine demographic and clinical information as well as laboratory data.
RESULTS: Overall, ADR occurred in six individuals (26.8%). Of the 15 patients who received ciprofloxacin therapy, none experienced ADR. In contrast, six of the nine patients who were treated with beta-lactam antibiotics experienced ADR including urticaria, elevated serum transaminase levels and neutropenia.
CONCLUSIONS: Prolonged antibiotic therapy for MEO with beta-lactam antibiotics is more likely to be complicated by ADR and requires careful monitoring.

Entities:  

Year:  2004        PMID: 15581748     DOI: 10.1016/j.ejim.2004.08.006

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  2 in total

1.  Malignant external otitis with extensive cranial neuropathy but no facial paralysis.

Authors:  Daniel Kondziella; Ina Skagervik
Journal:  J Neurol       Date:  2007-02-26       Impact factor: 4.849

Review 2.  Antibiotic therapy in necrotising external otitis: case series of 32 patients and review of the literature.

Authors:  C Pulcini; P Mahdyoun; E Cua; I Gahide; L Castillo; N Guevara
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-19       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.